C
Crescent Biopharma, Inc. (CBIO)
15.16
0.00 (0.00%)
Get all premium features to the best stock analysis tool
15.16
0.00 (0.00%)
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 6.56 | 6.05 | 10 | |
| Quick ratio | 6.56 | 5.63 | 10 | |
| Debt to Equity | 0.01 | 0.30 | 10 | |
| Debt to Assets | 0.01 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 75K | 10K | N/A | 11M | 11M |
| Gross Profit | -957K | -143K | N/A | 11M | 11M |
| Operating Income | -47M | -39M | -17M | -153M | -141M |
| Net Income | -47M | -37M | -18M | -154M | -141M |
| EBITDA | -46M | -39M | -17M | -153M | -141M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 95.07 | 5.5 |
| Next quarter | N/A | 81.25 | 5.5 |
| Current year | -86.83 | 71.72 | 5.5 |
| Next year | 279.17 | 4.31 | 7.0 |
| Weighted average score | 5.9 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -275.48 | -215.74 | -48.7 | 3.3 |
| Y/Y | 999 | -1179.24 | 49.88 | -627.62 | 5.5 |
| 3y average | 270.78 | -229.67 | 37.14 | -316.2 | 5.5 |
| 5y average | 126.05 | -137.38 | 25.85 | -195.16 | 5.5 |
| Weighted average score | 5.0 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $213.2M significantly exceed its total debt $1.6M, ensuring strong financial flexibility
Total current assets $236.7M exceed Total current liabilities $36.1M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$26.9M limits the company's ability to reinvest or pay down debt